{"pmid":32474555,"title":"Evaluation of RdRp & ORF-1b-nsp14-based real-time RT-PCR assays for confirmation of SARS-CoV-2 infection: An observational study.","text":["Evaluation of RdRp & ORF-1b-nsp14-based real-time RT-PCR assays for confirmation of SARS-CoV-2 infection: An observational study.","Indian J Med Res","Alagarasu, K","Choudhary, M L","Lole, K S","Abraham, Priya","Potdar, V","32474555"],"journal":"Indian J Med Res","authors":["Alagarasu, K","Choudhary, M L","Lole, K S","Abraham, Priya","Potdar, V"],"date":"2020-06-01T11:00:00Z","year":2020,"_id":"32474555","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.4103/ijmr.IJMR_1256_20","topics":["Diagnosis"],"weight":1,"_version_":1668341932719341568,"score":9.490897,"similar":[{"pmid":32276333,"pmcid":"PMC7177594","title":"Development of a Novel, Genome Subtraction-Derived, SARS-CoV-2-Specific COVID-19-nsp2 Real-Time RT-PCR Assay and Its Evaluation Using Clinical Specimens.","text":["Development of a Novel, Genome Subtraction-Derived, SARS-CoV-2-Specific COVID-19-nsp2 Real-Time RT-PCR Assay and Its Evaluation Using Clinical Specimens.","The pandemic novel coronavirus infection, Coronavirus Disease 2019 (COVID-19), has affected at least 190 countries or territories, with 465,915 confirmed cases and 21,031 deaths. In a containment-based strategy, rapid, sensitive and specific testing is important in epidemiological control and clinical management. Using 96 SARS-CoV-2 and 104 non-SARS-CoV-2 coronavirus genomes and our in-house program, GolayMetaMiner, four specific regions longer than 50 nucleotides in the SARS-CoV-2 genome were identified. Primers were designed to target the longest and previously untargeted nsp2 region and optimized as a probe-free real-time reverse transcription-polymerase chain reaction (RT-PCR) assay. The new COVID-19-nsp2 assay had a limit of detection (LOD) of 1.8 TCID50/mL and did not amplify other human-pathogenic coronaviruses and respiratory viruses. Assay reproducibility in terms of cycle threshold (Cp) values was satisfactory, with the total imprecision (% CV) values well below 5%. Evaluation of the new assay using 59 clinical specimens from 14 confirmed cases showed 100% concordance with our previously developed COVID-19-RdRp/Hel reference assay. A rapid, sensitive, SARS-CoV-2-specific real-time RT-PCR assay, COVID-19-nsp2, was developed.","Int J Mol Sci","Yip, Cyril Chik-Yan","Ho, Chi-Chun","Chan, Jasper Fuk-Woo","To, Kelvin Kai-Wang","Chan, Helen Shuk-Ying","Wong, Sally Cheuk-Ying","Leung, Kit-Hang","Fung, Agnes Yim-Fong","Ng, Anthony Chin-Ki","Zou, Zijiao","Tam, Anthony Raymond","Chung, Tom Wai-Hin","Chan, Kwok-Hung","Hung, Ivan Fan-Ngai","Cheng, Vincent Chi-Chung","Tsang, Owen Tak-Yin","Tsui, Stephen Kwok Wing","Yuen, Kwok-Yung","32276333"],"abstract":["The pandemic novel coronavirus infection, Coronavirus Disease 2019 (COVID-19), has affected at least 190 countries or territories, with 465,915 confirmed cases and 21,031 deaths. In a containment-based strategy, rapid, sensitive and specific testing is important in epidemiological control and clinical management. Using 96 SARS-CoV-2 and 104 non-SARS-CoV-2 coronavirus genomes and our in-house program, GolayMetaMiner, four specific regions longer than 50 nucleotides in the SARS-CoV-2 genome were identified. Primers were designed to target the longest and previously untargeted nsp2 region and optimized as a probe-free real-time reverse transcription-polymerase chain reaction (RT-PCR) assay. The new COVID-19-nsp2 assay had a limit of detection (LOD) of 1.8 TCID50/mL and did not amplify other human-pathogenic coronaviruses and respiratory viruses. Assay reproducibility in terms of cycle threshold (Cp) values was satisfactory, with the total imprecision (% CV) values well below 5%. Evaluation of the new assay using 59 clinical specimens from 14 confirmed cases showed 100% concordance with our previously developed COVID-19-RdRp/Hel reference assay. A rapid, sensitive, SARS-CoV-2-specific real-time RT-PCR assay, COVID-19-nsp2, was developed."],"journal":"Int J Mol Sci","authors":["Yip, Cyril Chik-Yan","Ho, Chi-Chun","Chan, Jasper Fuk-Woo","To, Kelvin Kai-Wang","Chan, Helen Shuk-Ying","Wong, Sally Cheuk-Ying","Leung, Kit-Hang","Fung, Agnes Yim-Fong","Ng, Anthony Chin-Ki","Zou, Zijiao","Tam, Anthony Raymond","Chung, Tom Wai-Hin","Chan, Kwok-Hung","Hung, Ivan Fan-Ngai","Cheng, Vincent Chi-Chung","Tsang, Owen Tak-Yin","Tsui, Stephen Kwok Wing","Yuen, Kwok-Yung"],"date":"2020-04-12T11:00:00Z","year":2020,"_id":"32276333","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.3390/ijms21072574","keywords":["covid-19","covid-19-nsp2 assay","golaymetaminer","sars-cov-2","clinical evaluation","genome subtraction","nsp2","real-time rt-pcr","sensitivity","specificity"],"topics":["Diagnosis"],"weight":1,"_version_":1666138491602337792,"score":54.672894},{"pmid":32489175,"title":"Letter to the editor: SARS-CoV-2 detection by real-time RT-PCR.","text":["Letter to the editor: SARS-CoV-2 detection by real-time RT-PCR.","Euro Surveill","Pillonel, Trestan","Scherz, Valentin","Jaton, Katia","Greub, Gilbert","Bertelli, Claire","32489175"],"journal":"Euro Surveill","authors":["Pillonel, Trestan","Scherz, Valentin","Jaton, Katia","Greub, Gilbert","Bertelli, Claire"],"date":"2020-06-04T11:00:00Z","year":2020,"_id":"32489175","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.2807/1560-7917.ES.2020.25.21.2000880","keywords":["covid-19","molecular diagnostic","sars-cov-2","real-time rt-pcr"],"link_comment_in":"32489177","link_comment_for":"31992387","topics":["Diagnosis"],"weight":1,"_version_":1668623433640968192,"score":53.42719},{"pmid":32350226,"title":"An assessment of real-time RT-PCR kits for SARS-CoV-2 detection.","text":["An assessment of real-time RT-PCR kits for SARS-CoV-2 detection.","The COVID-19 outbreak caused by SARS-CoV-2 in Wuhan (China) in December 2019 is currently spreading rapidly and globally. We recently reported a laboratory diagnostic protocol for SARS-CoV-2 based on real-time RT-PCR assays using two primer sets, N and N2. On 30-31 January 2020, the protocol and reagents for these assays were distributed to local public health institutes and quarantine depots in Japan, and nationwide, SARS-CoV-2 diagnostic testing was started. For further validation, the assays were compared with the commercially available kits using SARS CoV-2 viral RNA and the clinical specimens obtained from COVID19-suspected individuals. The LightMix Modular SARS and Wuhan CoV E-gene (LN S&W-E) assay was highly sensitive for SARS-CoV-2, as was the N2 set, and both assays had perfectly consistent results with the clinical specimens. While the LM S&W-E set targets the highly conserved region of the E gene in SARS-CoV and SARS-CoV-2, the N2 set was designed to target the unique region in the SARS-CoV-2 N gene. Thus, the N2 set has high specificity and sensitivity for SARS-CoV-2 detection. These indicate that the protocol using the N and N2 sets is comparable to commercially available kits and is reliable for the laboratory diagnosis of COVID-19.","Jpn J Infect Dis","Okamaoto, Kiyoko","Shirato, Kazuya","Nao, NagaNaganori","Saito, Shinji","Kageyama, Tsutomu","Hasegawa, Hideki","Suzuki, Tadaki","Matsuyama, Shutoku","Takeda, Makoto","32350226"],"abstract":["The COVID-19 outbreak caused by SARS-CoV-2 in Wuhan (China) in December 2019 is currently spreading rapidly and globally. We recently reported a laboratory diagnostic protocol for SARS-CoV-2 based on real-time RT-PCR assays using two primer sets, N and N2. On 30-31 January 2020, the protocol and reagents for these assays were distributed to local public health institutes and quarantine depots in Japan, and nationwide, SARS-CoV-2 diagnostic testing was started. For further validation, the assays were compared with the commercially available kits using SARS CoV-2 viral RNA and the clinical specimens obtained from COVID19-suspected individuals. The LightMix Modular SARS and Wuhan CoV E-gene (LN S&W-E) assay was highly sensitive for SARS-CoV-2, as was the N2 set, and both assays had perfectly consistent results with the clinical specimens. While the LM S&W-E set targets the highly conserved region of the E gene in SARS-CoV and SARS-CoV-2, the N2 set was designed to target the unique region in the SARS-CoV-2 N gene. Thus, the N2 set has high specificity and sensitivity for SARS-CoV-2 detection. These indicate that the protocol using the N and N2 sets is comparable to commercially available kits and is reliable for the laboratory diagnosis of COVID-19."],"journal":"Jpn J Infect Dis","authors":["Okamaoto, Kiyoko","Shirato, Kazuya","Nao, NagaNaganori","Saito, Shinji","Kageyama, Tsutomu","Hasegawa, Hideki","Suzuki, Tadaki","Matsuyama, Shutoku","Takeda, Makoto"],"date":"2020-05-01T11:00:00Z","year":2020,"_id":"32350226","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.7883/yoken.JJID.2020.108","keywords":["covid-19","sars-cov-2","real-time rt-pcr"],"locations":["Wuhan","China","Japan"],"countries":["Japan","China"],"countries_codes":["JPN|Japan","CHN|China"],"topics":["Diagnosis"],"weight":1,"_version_":1666138495593218048,"score":51.26191},{"pmid":32156329,"pmcid":"PMC7068162","title":"Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system.","text":["Evaluation of a quantitative RT-PCR assay for the detection of the emerging coronavirus SARS-CoV-2 using a high throughput system.","Facing the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), high-volume respiratory testing is demanded in laboratories worldwide. We evaluated the performance of a molecular assay for the detection of SARS-CoV-2 on a high-throughput platform, the cobas 6800, using the 'open channel' for integration of a laboratory-developed assay. We observed good analytical performance in clinical specimens. The fully automated workflow enables high-throughput testing with minimal hands-on time, while offering fast and reliable results.","Euro Surveill","Pfefferle, Susanne","Reucher, Svenja","Norz, Dominic","Lutgehetmann, Marc","32156329"],"abstract":["Facing the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), high-volume respiratory testing is demanded in laboratories worldwide. We evaluated the performance of a molecular assay for the detection of SARS-CoV-2 on a high-throughput platform, the cobas 6800, using the 'open channel' for integration of a laboratory-developed assay. We observed good analytical performance in clinical specimens. The fully automated workflow enables high-throughput testing with minimal hands-on time, while offering fast and reliable results."],"journal":"Euro Surveill","authors":["Pfefferle, Susanne","Reucher, Svenja","Norz, Dominic","Lutgehetmann, Marc"],"date":"2020-03-12T11:00:00Z","year":2020,"_id":"32156329","source":"PubMed","week":"202011|Mar 09 - Mar 15","doi":"10.2807/1560-7917.ES.2020.25.9.2000152","keywords":["covid-19","sars-cov-2","automation","high-throughput pcr","molecular diagnostic"],"link_comment_for":"31992387","topics":["Diagnosis"],"weight":1,"_version_":1666138492686565376,"score":48.185482},{"pmid":31992387,"pmcid":"PMC6988269","title":"Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.","text":["Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.","BACKGROUND: The ongoing outbreak of the recently emerged novel coronavirus (2019-nCoV) poses a challenge for public health laboratories as virus isolates are unavailable while there is growing evidence that the outbreak is more widespread than initially thought, and international spread through travellers does already occur. AIM: We aimed to develop and deploy robust diagnostic methodology for use in public health laboratory settings without having virus material available. METHODS: Here we present a validated diagnostic workflow for 2019-nCoV, its design relying on close genetic relatedness of 2019-nCoV with SARS coronavirus, making use of synthetic nucleic acid technology. RESULTS: The workflow reliably detects 2019-nCoV, and further discriminates 2019-nCoV from SARS-CoV. Through coordination between academic and public laboratories, we confirmed assay exclusivity based on 297 original clinical specimens containing a full spectrum of human respiratory viruses. Control material is made available through European Virus Archive - Global (EVAg), a European Union infrastructure project. CONCLUSION: The present study demonstrates the enormous response capacity achieved through coordination of academic and public laboratories in national and European research networks.","Euro Surveill","Corman, Victor M","Landt, Olfert","Kaiser, Marco","Molenkamp, Richard","Meijer, Adam","Chu, Daniel Kw","Bleicker, Tobias","Brunink, Sebastian","Schneider, Julia","Schmidt, Marie Luisa","Mulders, Daphne Gjc","Haagmans, Bart L","van der Veer, Bas","van den Brink, Sharon","Wijsman, Lisa","Goderski, Gabriel","Romette, Jean-Louis","Ellis, Joanna","Zambon, Maria","Peiris, Malik","Goossens, Herman","Reusken, Chantal","Koopmans, Marion Pg","Drosten, Christian","31992387"],"abstract":["BACKGROUND: The ongoing outbreak of the recently emerged novel coronavirus (2019-nCoV) poses a challenge for public health laboratories as virus isolates are unavailable while there is growing evidence that the outbreak is more widespread than initially thought, and international spread through travellers does already occur. AIM: We aimed to develop and deploy robust diagnostic methodology for use in public health laboratory settings without having virus material available. METHODS: Here we present a validated diagnostic workflow for 2019-nCoV, its design relying on close genetic relatedness of 2019-nCoV with SARS coronavirus, making use of synthetic nucleic acid technology. RESULTS: The workflow reliably detects 2019-nCoV, and further discriminates 2019-nCoV from SARS-CoV. Through coordination between academic and public laboratories, we confirmed assay exclusivity based on 297 original clinical specimens containing a full spectrum of human respiratory viruses. Control material is made available through European Virus Archive - Global (EVAg), a European Union infrastructure project. CONCLUSION: The present study demonstrates the enormous response capacity achieved through coordination of academic and public laboratories in national and European research networks."],"journal":"Euro Surveill","authors":["Corman, Victor M","Landt, Olfert","Kaiser, Marco","Molenkamp, Richard","Meijer, Adam","Chu, Daniel Kw","Bleicker, Tobias","Brunink, Sebastian","Schneider, Julia","Schmidt, Marie Luisa","Mulders, Daphne Gjc","Haagmans, Bart L","van der Veer, Bas","van den Brink, Sharon","Wijsman, Lisa","Goderski, Gabriel","Romette, Jean-Louis","Ellis, Joanna","Zambon, Maria","Peiris, Malik","Goossens, Herman","Reusken, Chantal","Koopmans, Marion Pg","Drosten, Christian"],"date":"2020-01-30T11:00:00Z","year":2020,"_id":"31992387","source":"PubMed","week":"20205|Jan 27 - Feb 02","doi":"10.2807/1560-7917.ES.2020.25.3.2000045","keywords":["2019-ncov","rt-pcr","wuhan","diagnostics","laboratory","novel coronavirus","outbreak","testing"],"link_comment_in":"32347201","topics":["Diagnosis"],"weight":1,"_version_":1666138493070344192,"score":46.813675}]}